Recent developments in the pathology of Parkinson’s disease

2002 ◽  
pp. 347-384 ◽  
Author(s):  
K. A. Jellinger
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Recent Developments

scholarly journals The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses

2021 ◽  
Vol 22 (15) ◽  
pp. 8338
Author(s):  
Asad Jan ◽  
Nádia Pereira Gonçalves ◽  
Christian Bjerggaard Vaegter ◽  
Poul Henning Jensen ◽  
Nelson Ferreira
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Mechanisms ◽  
De Novo ◽  
Alpha Synuclein ◽  
Experimental Models ◽  
Cellular Factors ◽  
Recent Developments ◽  
Novel Targets ◽  
Presynaptic Protein

The pathological aggregation of the presynaptic protein α-synuclein (α-syn) and propagation through synaptically coupled neuroanatomical tracts is increasingly thought to underlie the pathophysiological progression of Parkinson’s disease (PD) and related synucleinopathies. Although the precise molecular mechanisms responsible for the spreading of pathological α-syn accumulation in the CNS are not fully understood, growing evidence suggests that de novo α-syn misfolding and/or neuronal internalization of aggregated α-syn facilitates conformational templating of endogenous α-syn monomers in a mechanism reminiscent of prions. A refined understanding of the biochemical and cellular factors mediating the pathological neuron-to-neuron propagation of misfolded α-syn will potentially elucidate the etiology of PD and unravel novel targets for therapeutic intervention. Here, we discuss recent developments on the hypothesis regarding trans-synaptic propagation of α-syn pathology in the context of neuronal vulnerability and highlight the potential utility of novel experimental models of synucleinopathies.

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease

Drugs ◽  
2019 ◽  
Vol 79 (10) ◽  
pp. 1037-1051 ◽  
Author(s):  
Ye Zhao ◽  
Nicolas Dzamko
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Targeted Therapy ◽  
Recent Developments

scholarly journals Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review

Gerontology ◽  
2015 ◽  
Vol 62 (3) ◽  
pp. 371-380 ◽  
Author(s):  
Michael D. Staudt ◽  
Andrea R. Di Sebastiano ◽  
Hu Xu ◽  
Mandar Jog ◽  
Susanne Schmid ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Therapeutic Agents ◽  
The Past ◽  
Cell Based Therapy ◽  
Recent Developments ◽  
Biological Sources ◽  
And Function ◽  
Disease Modifying Treatment ◽  
Host Brain

Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.

scholarly journals The Cell Biology of LRRK2 in Parkinson’s Disease

2021 ◽  
Author(s):  
Ahsan Usmani ◽  
Farbod Shavarebi ◽  
Annie Hiniker
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Biology ◽  
Kinase Inhibitor ◽  
Genetic Model ◽  
Point Mutations ◽  
Model Systems ◽  
Rab Gtpases ◽  
Recent Developments ◽  
Lrrk2 Kinase

Point mutations in Leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD) and are implicated in a significant portion of apparently sporadic PD. Clinically, LRRK2-driven PD is indistinguishable from sporadic PD, making it an attractive genetic model for the much more common sporadic PD. In this review, we highlight recent advances in understanding LRRK2's subcellular functions using LRRK2-PD models, while also considering some of the limitations of these model systems. Recent developments of particular importance include new evidence of key LRRK2 functions in the endolysosomal system and LRRK2’s regulation of and by Rab GTPases. Additionally, LRRK2's interaction with the cytoskeleton allowed elucidation of the LRRK2 structure and appears relevant to LRRK2 protein degradation and LRRK2 kinase inhibitor therapies. We further discuss how LRRK2's interactions with other PD-driving genes, such as VPS35, GCase, and α-synuclein, may highlight cellular pathways more broadly disrupted in PD.

Psychiatric side-effects of medications: recent developments

2005 ◽  
Vol 11 (1) ◽  
pp. 58-70 ◽  
Author(s):  
Nora Turjanski ◽  
Geoffrey G. Lloyd
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Hiv Infection ◽  
Recent Developments ◽  
Psychiatric Side Effects ◽  
Neuropsychiatric Side Effects

Medications often induce neuropsychiatric side-effects. This article reviews psychiatric side-effects that are well known and describes those induced by recently developed medications. Therapeutic innovations have been prominent in the treatment of HIV infection, Parkinson's disease and epilepsy and therefore psychiatric side-effects caused by these agents are described in more detail.

Recent developments in circulating biomarkers in Parkinson’s disease: the potential use of miRNAs in a clinical setting

Bioanalysis ◽  
2016 ◽  
Vol 8 (23) ◽  
pp. 2497-2518 ◽  
Author(s):  
Marcia Cristina Teixeira dos Santos ◽  
Rosie Bell ◽  
Andre Nogueira da Costa
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Setting ◽  
Circulating Biomarkers ◽  
Recent Developments ◽  
Potential Use

scholarly journals Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients

2020 ◽  
Vol 14 ◽  
Author(s):  
Teresia M. Osborn ◽  
Penelope J. Hallett ◽  
James M. Schumacher ◽  
Ole Isacson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Therapy ◽  
Autologous Cell ◽  
Recent Developments ◽  
Autologous Cell Therapy
Sign in / Sign up

Export Citation Format

Share Document